同: Prostigmin

WordNet

a cholinergic drug (trade name Prostigmin) used to treat some ophthalmic conditions and to treat myasthenia gravis (同)Prostigmin

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. Respiratory problems in the post-anesthesia care unit (PACU)
2. 急性偽性腸閉塞（オギルビー症候群） acute colonic pseudo obstruction ogilvies syndrome
3. Cardiovascular problems in the post-anesthesia care unit (PACU)
4. 重症筋無力症患者に対する麻酔 anesthesia for the patient with myasthenia gravis
5. 慢性偽性腸閉塞 chronic intestinal pseudo obstruction

English Journal

Combined treatment with anisodamine and neostigmine inhibits joint inflammation in collagen-induced arthritis mice.

Zhou JX, Ke P, Huan G, Shao BZ, Liu C.
CNS neuroscience & therapeutics.CNS Neurosci Ther.2014 Feb;20(2):186-7. doi: 10.1111/cns.12213. Epub 2014 Jan 7.
PMID 24393231

Modified carbon paste sensor for the potentiometric determination of neostigmine bromide in pharmaceutical formulations, human plasma and urine.

Khorshid AF, Issa YM.Author information Pharmaceutical Analytical Chemistry Department, Faculty of Clinical Pharmacy, Nahda University, NUB, Beni-Sweff, Egypt. Electronic address: amalkorshid@yahoo.com.AbstractA novel, simple, rapid, selective and sensitive method for the determination of neostigmine (Ns) ion in its bulk powder, different pharmaceutical dosage forms, and biological fluids (plasma and urine) using four modified carbon paste electrodes was developed. Sensor 1 is based on ion-association Ns-TPB, sensor 2 used Ns-PT, sensor 3 comprises a mixture of (Ns-PT+Ns-TPB) and sensor 4 was constructed using (Ns-PT+β-CD). Solvent mediator 2-NPPE exhibited a proper behavior including Nernstian slope ranging from 61.5±0.5 to 64.5±0.5 mV per decade over the pH range of 3.8-10 for the four sensors. Linear responses of Ns within the concentration range 1.0×10(-7)-1.0×10(-2) mol/L were obtained. The response time is very short (≤10s) with a detection limit 6.3×10(-8) M. In flow injection analysis (FIA), sensor 3 shows a Nernstian slope value 75.5±0.5 mV per decade within the concentration range of 1×10(-6)-1×10(-2) mol/L and with a detection limit 7.5×10(-7) mol/L. The utility of mixed or additives of β-CD had a significant influence on increasing the sensitivity of sensors 3 and 4 compared to sensors 1 and 2. The sensors were applied for the determination of neostigmine (Ns) ion in its bulk powder, different pharmaceutical dosage forms, and biological fluids (plasma and urine). The results obtained were satisfactory with excellent percentage recovery comparable with official method for the assay based on non-aqueous titration using perchloric acid as a titrant.
Biosensors & bioelectronics.Biosens Bioelectron.2014 Jan 15;51:143-9. doi: 10.1016/j.bios.2013.07.018. Epub 2013 Jul 20.
A novel, simple, rapid, selective and sensitive method for the determination of neostigmine (Ns) ion in its bulk powder, different pharmaceutical dosage forms, and biological fluids (plasma and urine) using four modified carbon paste electrodes was developed. Sensor 1 is based on ion-association Ns-
PMID 23948245

Management of faecal incontinence and constipation in adults with central neurological diseases.

Coggrave M, Norton C, Cody JD.Author information The National Spinal Injuries Centre, Stoke Mandeville Hospital, Aylesbury and Buckinghamshire New University, Aylesbury, Buckinghamshire, UK, HP21 8AL.AbstractBACKGROUND: People with central neurological disease or injury have a much higher risk of both faecal incontinence and constipation than the general population. There is often a fine line between the two symptoms, with any management intended to ameliorate one risking precipitating the other. Bowel problems are observed to be the cause of much anxiety and may reduce quality of life in these people. Current bowel management is largely empirical, with a limited research base. This is an update of a Cochrane review first published in 2001 and subsequently updated in 2003 and 2006. The review is relevant to individuals with any disease directly and chronically affecting the central nervous system (post-traumatic, degenerative, ischaemic or neoplastic), such as multiple sclerosis, spinal cord injury, cerebrovascular disease, Parkinson's disease and Alzheimer's disease.
The Cochrane database of systematic reviews.Cochrane Database Syst Rev.2014 Jan 13;1:CD002115. [Epub ahead of print]
BACKGROUND: People with central neurological disease or injury have a much higher risk of both faecal incontinence and constipation than the general population. There is often a fine line between the two symptoms, with any management intended to ameliorate one risking precipitating the other. Bowel
PMID 24420006